Pharsight

Nityr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10328029 CYCLE PHARMS LTD Pharmaceutical composition
Jan, 2035

(10 years from now)

Nityr is owned by Cycle Pharms Ltd.

Nityr contains Nitisinone.

Nityr has a total of 1 drug patent out of which 0 drug patents have expired.

Nityr was authorised for market use on 26 July, 2017.

Nityr is available in tablet;oral dosage forms.

Nityr can be used as treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine.

The generics of Nityr are possible to be released after 05 January, 2035.

Drugs and Companies using NITISINONE ingredient

Market Authorisation Date: 26 July, 2017

Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Dosage: TABLET;ORAL

More Information on Dosage

NITYR family patents

Family Patents